Washington, DC - A new Ipsos Global @dvisor poll among citizens of 25 countries sheds light on who influences global affairs in this dangerous world.
An overwhelming majority (86%) of respondents in 25 countries around the world agree that over the last year the world became more dangerous. Since October 2016, the number of those who agree increased most notably in Brazil (95%, +14 pts.), South Korea (94%, +10 pts.), Germany (90%, +8 pts.) and Australia (89%, +8 pts.). Respondents in Russia (78%, -7 pts.), France (81%, -6 pts.) and Hungary (85%, -5 pts.) view the world as a less dangerous place now compared to 2016.
Majority of respondents around the world put Canada (81%) at the top of the list of countries and organizations that have positive influence on world affairs today. While Canada's positive influence score remains the same since 2016, all other countries and organizations experience a decline since last sounding*, most notably the United States (40%, - 24 pts.), France (59%, -12 pts.), Russia (35%, -11 pts.) and United Nations (64%, - 9pts.)
About the Study
The survey instrument is conducted monthly in 25 countries around the world via the Ipsos Online Panel system. The countries reporting herein are Argentina, Australia, Belgium, Brazil, Canada, China, France, Great Britain, Germany, Hungary, India, Italy, Japan, Mexico, New Zealand, Peru, Poland, Russia, Serbia, South Africa, South Korea, Spain, Sweden, Turkey and the United States of America.
For the results of the survey presented herein, an international sample of 18,055 adults aged 18-64 in the US and Canada, and age 16-64 in all other countries, were interviewed between April 21st and May 5th. Approximately 1000+ individuals participated on a country by country basis via the Ipsos Online Panel with the exception of Argentina, Belgium, Hungary, India, Mexico, New Zealand, Peru, Poland, Russia, Serbia, South Africa, South Korea, Sweden and Turkey, where each have a sample approximately 500+. The precision of Ipsos online polls are calculated using a credibility interval with a poll of 1,000 accurate to +/- 3.5 percentage points and of 500 accurate to +/- 5.0 percentage points. For more information on the Ipsos use of credibility intervals, please visit the Ipsos website.
16 of the 24 countries surveyed generate nationally representative samples in their countries (Argentina, Australia, Belgium, Canada, France, Germany, Great Britain, Hungary, Italy, Japan, New Zealand, Poland, South Korea, Spain, Sweden, and United States).
Brazil, China, India, Mexico, Peru, Russia, Serbia, South Africa and Turkey produce a national sample that is more urban & educated, and with higher incomes than their fellow citizens. We refer to these respondents as “Upper Deck Consumer Citizens”. They are not nationally representative of their country.
For more information on this news release, please contact:
Senior Research Manager
Ipsos Public Affairs
Ipsos is an independent market research company controlled and managed by research professionals. Founded in France in 1975, Ipsos has grown into a worldwide research group with a strong presence in all key markets. Ipsos ranks third in the global research industry.
With offices in 87 countries, Ipsos delivers insightful expertise across five research specializations: brand, advertising and media, customer loyalty, marketing, public affairs research, and survey management.
Ipsos researchers assess market potential and interpret market trends. They develop and build brands. They help clients build long-term relationships with their customers. They test advertising and study audience responses to various media and they measure public opinion around the globe.
Ipsos has been listed on the Paris Stock Exchange since 1999 and generated global revenues €1,669.5 ($2,218.4 million) in 2014.
Visit www.ipsos.com to learn more about Ipsos’ offerings and capabilities.
[WEBINAR] Messaging & Motivation: Engaging Participants in Healthcare Research
One of the biggest challenges researchers face is recruiting and retaining participants, especially for longitudinal studies or intense clinical trials. Join us for a complimentary webinar to learn innovative ways to enhance recruitment, and maintain participant engagement.